Navigation Links
Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Date:7/29/2008

FRANKLIN, Mass., July 29 /PRNewswire-FirstCall/ -- Echo Therapeutics (OTC Bulletin Board: ECTE) today announced positive results of a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring (tCGM) System in patients with Type 1 and Type 2 Diabetes. Echo's non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and the Prelude(TM) SkinPrep System, which incorporates leading-edge, needle-free skin permeation control. Echo's Symphony tCGM System is designed to provide both diabetics and hospital patients with a reliable, affordable, comfortable-to-wear, and easy-to-use, needle-free continuous glucose monitoring device.

"This study represents another major advancement in our Prelude and Symphony development programs," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We have now successfully used Prelude, our new needle-free skin preparation system, in combination with our non-invasive Symphony tCGM technology. Data from this study demonstrate that Symphony, using Prelude, is safe, accurate and reliable at monitoring glucose levels. We look forward to continuing progress with our Symphony development program throughout the year."

Study Design

After Prelude skin permeation, Symphony tCGM biosensors were applied to ten subjects with Type 1 or Type 2 diabetes. Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300STAT PLUS laboratory analyzer. At the conclusion of the 24-hour observation period, the test skin sites were inspected for redness or any other undesirable effects.

Analytical Methods

The primary statistical analysis tools used to evaluate the performance of the Symphony tCGM System relative to the reference measurements were the Clarke error grid, mean absolute relative difference (MARD) and linear regression, each of which are widely used to evaluate the performance of
'/>"/>

SOURCE Echo Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...PRNewswire/--ACUOTECHNOLOGIES,developersofhigh-per...ontoolsandservices,ispleasedtoannouncethattheUnite...pplicationforan"AssetCommunicationFormatwithinaCom....patenttoitsportfolioofintellectualproperty.Ingene...,stechnologyanduseofassetmetainformationtocontrolr...
(Date:11/25/2009)...Newswire-FirstCall/--HeskaCorporation(HSKA);("Hesk...altyproductstotheveterinaryindustry,announcedtoday...plyofbloodgasproductsandaffiliatedconsumablesforth....com/cgi-bin/prnh/20000622/HESKALOGO ) ,, "Hesk...dofadvancedpoint-of-carediagnostics,"commentedMich...
(Date:11/25/2009)...ire/--BioTrendsResearchGroup,Inc.releasedWave1ofit...amulti-phasesyndicatedmarketresearchprojecttrackin...ductlaunchthroughthefirstsixmonthsofavailability.E...rom75uniqueDermatologistsandqualitativeinformation...ra,obstaclestouse,typicalpatienttypes,productperce...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v Levine and Pandemic Influenza 48072 1DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v Levine and Pandemic Influenza 48072 2DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v Levine and Pandemic Influenza 48072 3Government of Canada announces funding for research on the H1N1 flu virus 8732 1Government of Canada announces funding for research on the H1N1 flu virus 8732 2Ludwig Institute of Cancer Research Ltd Brussels Branch Issues Statement Concerning Prospect Therapeutics Incs GCS 100 Molecule 48071 1Ludwig Institute of Cancer Research Ltd Brussels Branch Issues Statement Concerning Prospect Therapeutics Incs GCS 100 Molecule 48071 2
...x S.A.,(Eurolist: COX) today announced that Merck ... planned clinical studies, in mild to moderate,hyp...tive agreement to,develop new nitric oxide-donatin...technology. Three drug candidates have now been se... of which two have completed initial,dose ranging ...
...n Prevention Business, DUBLIN, Ohio, May 12 Card...vices that improve the safety and,productivity of ...acquisition of assets of privately held Enturia, I...ucts sold under the ChloraPrep(R) brand name., Ch... hospitals and,surgery centers as a patient preope...
Other Medicine Technology:NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Cardinal Health Completes Enturia Acquisition 2
(Date:11/27/2009)... Biotech firm Replikins Ltd. tod...1N1 virus genomic data. It shows that the lethali...s.d. 4.5) during the virus,s current outbreak in t...his week of 2.0 (s.d. 0.1). The H1N1 infectivity c... Boston (PRWEB) November 27, 2009 -- Bio...
(Date:11/27/2009)... NEUILLY-SUR-SEINE,France,Nov.27/PRNewswire/--Team...ingteamdedicatedtoethicalsportinganddevelopingthen...itwillbecomeTeamGarmin-Transitionswiththeadditiono...onsOpticalistheworld,sleadingmanufacturerofadaptiv...logyinthewidestselectionofspectaclelensessuchasTra...
(Date:11/27/2009)... rates to bring unprecedented medical, economic bu...7 (HealthDay News) -- The number of people with di...over the next 25 years, a new study predicts. ,...million people with the disease, up from 23.7 mill...ating people with diabetes will triple, the study ...
(Date:11/27/2009)... Specialist manufacturers who us...s are saving millions of dollars by bringing in te...ss. Increasing numbers of pro-active medical manuf...at the concept stage of their projects, ensuring t...esign processes or potentially outdated technology...
(Date:11/26/2009)...e next 25 years, the number of Americans living wi....7 million in 2009 to 44.1 million in 2034. Over t...riple, rising from $113 billion to $336 billion, e... researchers based at the University of Chicago re... The number of those with diabetes covered by Medi...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...ent an important contribution to future clinical t...the prestigious science journal Nature and will ...on the molecular mechanisms of hematopoiesis, whic...n Munich at the international symposium "Molecular...
...sAbilities Resources champions company,s efforts ,...ed the 2009 Disability Matters Award in the catego...ment to supporting people with disabilities and th...and its employee network group, Sodexo Organizatio...
... to treat a mid-level, common injury , , ROSEMON...ions can commonly be treated nonsurgically and hig...re review published in the April 2009 issue of the...se injuries that fall in between. , , , , ...
... Immunotech Laboratories, Inc. , , Immunotech La...DART conference in Puerto Rico with its abstract ...ificant antiretroviral activity via specific novel...ence on Clinical and Social Research on AIDS and D...
... Awareness among Hispanic Community as Fewer Recei...Easter Seals is shining the spotlight on its servi...vast array of services, the national nonprofit pro...ren and adults with autism the organization serves...
..., Self-administered Alternative to Injections for ... LAKE, N.J., April 1 Strativa Pharmaceuticals, th...subsidiary of Par Pharmaceutical Companies, Inc. (...Nasal Spray is an FDA approved prescription vitami...
Other Medicine News:Health News:Last step leading to blood cell formation elucidated 2Health News:Sodexo Receives 2009 Disability Matters Award 2Health News:Sodexo Receives 2009 Disability Matters Award 3Health News:Healing a Shoulder Separation 2Health News:Healing a Shoulder Separation 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 2Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 3Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 4
...garose gels to hybridization membranes in as littl... transfer by allowing high pressure to be applied ...trophoresis, gel treatment, transfer and UV crossl...conventional methods ,Positive pressure drives buf...
Trans-Blot Plus Gel/Cassette Assembly Tray
Criterion Gel Holder Cassettes 2
...analysis ,The ProfiBlot is a fully automated ...ing the detection of proteins that reveal the pres...cteria. Furthermore ProfiBlot enables fast and acc... areas that are rapidly expanding. ,The system o...
Medicine Products: